156 related articles for article (PubMed ID: 36601038)
21. Outcomes After Cryoablation Versus Partial Nephrectomy for Sporadic Renal Tumors in a Solitary Kidney: A Propensity Score Analysis.
Bhindi B; Mason RJ; Haddad MM; Boorjian SA; Leibovich BC; Atwell TD; Weisbrod AJ; Schmit GD; Thompson RH
Eur Urol; 2018 Feb; 73(2):254-259. PubMed ID: 28967553
[TBL] [Abstract][Full Text] [Related]
22. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
23. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
[TBL] [Abstract][Full Text] [Related]
24. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
[TBL] [Abstract][Full Text] [Related]
25. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
26. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses.
Andrews JR; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2019 Aug; 76(2):244-251. PubMed ID: 31060824
[TBL] [Abstract][Full Text] [Related]
27. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
28. Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell Carcinoma.
Tanaka H; Fukuda S; Kimura K; Fukawa Y; Yamamoto K; Fukushima H; Moriyama S; Yasuda Y; Uehara S; Waseda Y; Yoshida S; Yokoyama M; Matsuoka Y; Saito K; Tateishi U; Campbell SC; Fujii Y
Eur Urol Open Sci; 2023 Feb; 48():36-43. PubMed ID: 36743398
[TBL] [Abstract][Full Text] [Related]
29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
30. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes.
Psutka SP; Heidenreich M; Boorjian SA; Bailey GC; Cheville JC; Stewart-Merrill SB; Lohse CM; Atwell TD; Costello BA; Leibovich BC; Thompson RH
BJU Int; 2017 Jan; 119(1):116-127. PubMed ID: 27489013
[TBL] [Abstract][Full Text] [Related]
31. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.
Weight CJ; Kim SP; Lohse CM; Cheville JC; Thompson RH; Boorjian SA; Leibovich BC
Eur Urol; 2011 Sep; 60(3):458-64. PubMed ID: 21514718
[TBL] [Abstract][Full Text] [Related]
32. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
33. A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy.
Kim SH; Choi MG; Shin JH; Kim YA; Chung J
Front Oncol; 2021; 11():693831. PubMed ID: 34568023
[TBL] [Abstract][Full Text] [Related]
34. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
35. Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients.
Kuijpers YA; Meijer RP; Jonges GN; de Jong J; Bosch JL; Horenblas S; Bex A
World J Urol; 2016 Aug; 34(8):1073-9. PubMed ID: 27055532
[TBL] [Abstract][Full Text] [Related]
36. Survival And Progression After Radical Nephrectomy In A Cohort Of Non-Metastatic Renal Cell Carcinoma Treated With Curative Intent.
Khan N; Irshad Khalil MA; Ali A; Manzoor S; Urooj N; Mir K
J Ayub Med Coll Abbottabad; 2019; 31(3):314-319. PubMed ID: 31535497
[TBL] [Abstract][Full Text] [Related]
37. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
38. Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities.
Liu Y; Zhang X; Ma H; Tian L; Mai L; Long W; Zhang Z; Han H; Zhou F; Dong P; He L
Cancer Med; 2022 Dec; 11(23):4430-4439. PubMed ID: 35506551
[TBL] [Abstract][Full Text] [Related]
39. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
[TBL] [Abstract][Full Text] [Related]
40. Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence".
Bertolo R; Nicolas M; Garisto J; Magi-Galluzzi C; McKenney JK; Kaouk J
Clin Genitourin Cancer; 2019 Jun; 17(3):209-215.e1. PubMed ID: 31000486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
